a Department of Dermatology , University of California San Francisco , San Francisco , CA , USA.
Hum Vaccin Immunother. 2017 Oct 3;13(10):2247-2259. doi: 10.1080/21645515.2017.1356498.
Psoriasis is a chronic, inflammatory, immune-mediated skin condition that affects 3 to 4% of the adult US population, characterized by well-demarcated, erythematous plaques with silver scale. Psoriasis is associated with many comorbidities including cardiometabolic disease and can have a negative impact on quality of life. The current armamentarium of psoriasis treatment includes topical therapies, phototherapy, oral immunosuppressive therapies, and biologic agents. Over the past 2 decades, there has been rapid development of novel biologic therapies for the treatment of moderate-to-severe plaque psoriasis. This article will review the role of IL-12, IL-23, and IL-17 in the pathogenesis of psoriasis and the monoclonal antibodies (ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, and risankizumab) that target these cytokines in the treatment of this disease.
银屑病是一种慢性、炎症性、免疫介导的皮肤疾病，影响 3%至 4%的美国成年人，其特征是边界清楚的红斑斑块，伴有银色鳞屑。银屑病与许多合并症有关，包括心血管代谢疾病，并会对生活质量产生负面影响。目前银屑病的治疗方法包括局部治疗、光疗、口服免疫抑制剂治疗和生物制剂。在过去的 20 年中，针对中度至重度斑块状银屑病的新型生物疗法发展迅速。本文将回顾白细胞介素-12、白细胞介素-23 和白细胞介素-17 在银屑病发病机制中的作用，以及针对这些细胞因子的单克隆抗体（乌司奴单抗、司库奇尤单抗、依奇珠单抗、布罗达单抗、古塞库单抗、替利珠单抗和 risankizumab）在该疾病治疗中的作用。
